For the quarter ending 2025-09-30, UTHR had -$253,000K decrease in cash & cash equivalents over the period. $351,600K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 338,700 | 631,700 |
| Depreciation and amortization | 21,900 | 40,900 |
| Share-based compensation expense | 39,100 | 69,600 |
| Impairment of property, plant, and equipment | 0 | 21,700 |
| Other | 100 | -14,000 |
| Accounts receivable | -81,600 | 100,000 |
| Inventories | 17,500 | 18,600 |
| Accounts payable and accrued expenses | 31,200 | 43,500 |
| Other assets and liabilities | -67,200 | 49,900 |
| Net cash provided by operating activities | 562,100 | 652,900 |
| Purchases of property, plant, and equipment | 210,500 | 137,100 |
| Acquired lease intangible assets | 5,500 | - |
| Deposits | 5,700 | 9,800 |
| Purchases of available-for-sale debt securities | 385,900 | 2,499,200 |
| Maturities of available-for-sale debt securities | 182,500 | 915,900 |
| Sales of available-for-sale debt securities | 596,000 | 1,265,600 |
| Purchase of investment in privately-held company | 30,000 | 0 |
| Net cash (used in) provided by investing activities | 140,900 | -464,600 |
| Payments to repurchase common stock | 1,000,000 | 0 |
| Proceeds from line of credit | 0 | 200,000 |
| Repayment of line of credit | 0 | 500,000 |
| Excise tax paid on net share repurchase | 0 | 5,000 |
| Payments of debt issuance costs | 0 | 11,500 |
| Proceeds from the exercise of stock options | 40,200 | 34,700 |
| Proceeds from the issuance of stock under espp | 4,300 | 4,900 |
| Rsus withheld for taxes | 500 | 15,500 |
| Net cash used in financing activities | -956,000 | -292,400 |
| Net (decrease) increase in cash and cash equivalents | -253,000 | -104,100 |
| Cash and cash equivalents at beginning of period | 1,697,200 | - |
| Cash and cash equivalents at end of period | 1,340,100 | - |
UNITED THERAPEUTICS Corp (UTHR)
UNITED THERAPEUTICS Corp (UTHR)